Evidence map›Paper›PMID 36952047›Full record

ArticleSurgical endoscopy2023

Ursodeoxycholic acid for prevention of gallstone disease after laparoscopic sleeve gastrectomy: an Atlantic Canada perspective.

Intekhab Hossain, Jane Brodie, Erin O'Brien, Katherine Tedman-Aucoin, Diana Lawlor, Raleen Murphy, Laurie Twells, David Pace, Bradley Evans, James Ellsmere

Abstract read
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Intekhab HossainDepartment of Surgery, Memorial University, 300 Prince Phillip Drive, St. John's, NL, A1B 3V6, Canada.
Jane BrodieDepartment of Surgery, Memorial University, 300 Prince Phillip Drive, St. John's, NL, A1B 3V6, Canada.
Erin O'BrienDepartment of Surgery, Memorial University, 300 Prince Phillip Drive, St. John's, NL, A1B 3V6, Canada.
Katherine Tedman-AucoinDepartment of Surgery, Dalhousie University, Halifax, NS, Canada.
Diana LawlorDepartment of Surgery, Dalhousie University, Halifax, NS, Canada.
Raleen MurphyDepartment of Surgery, Memorial University, 300 Prince Phillip Drive, St. John's, NL, A1B 3V6, Canada.
Laurie TwellsFaculty of Medicine, Memorial University, St. John's, NL, Canada.
David PaceDepartment of Surgery, Memorial University, 300 Prince Phillip Drive, St. John's, NL, A1B 3V6, Canada.
Bradley EvansDepartment of Surgery, Memorial University, 300 Prince Phillip Drive, St. John's, NL, A1B 3V6, Canada. b.evans@mun.ca.
James EllsmereDepartment of Surgery, Dalhousie University, Halifax, NS, Canada.
Memorial University of Newfoundland · CADalhousie University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProphylactic ursodeoxycholic acid (UDCA) may be beneficial in reducing gallstone disease after bariatric surgery. The American Society for Metabolic and Bariatric Surgery (ASMBS) 2019 guidelines recommend a 6-month course of UDCA for patients undergoing laparoscopic sleeve gastrectomy (LSG). This has not been adopted broadly. This study intends to assess the effect of routine UDCA administration following LSG on symptomatic gallstone disease.

methodsWe performed a retrospective chart review of patients who underwent LSG, between 2009 and 2019, at two tertiary care centers in Atlantic Canada. At one center, UDCA 250 mg oral twice daily was routinely prescribed following LSG for 6 months to patients with an intact gallbladder. At the other center, UDCA was not prescribed. Primary and secondary outcomes were cholecystectomy and endoscopic retrograde cholangiopancreatography (ERCP) rates. Compliance with and side effects of UDCA therapy were analyzed.

resultsA total of 751 patients were included in the study. Patients who had prior cholecystectomy or were lost to follow up were excluded. After exclusion criteria were applied, 461 patients were included for analysis: 303 in the UDCA group and 158 in the group who did not receive UDCA. Cholecystectomy rate was not significantly associated with UDCA administration, however there was a trend towards less cholecystectomy in patients who received UDCA (8.3% vs. 13.9%, p = 0.056). ERCP rate was significantly lower in patients who received UDCA (0.3% vs 2.5%, p = 0.031). Rate of gallstone disease requiring intervention, either cholecystectomy or ERCP, was significantly decreased in patients who received UDCA (8.9% vs 15.8%, p = 0.022). The most common barriers to compliance with UDCA were cost (45.4%) and nausea (18.1%).

conclusionThis is the first study to demonstrate lower rates of ERCP in patients receiving routine UDCA following LSG. Our findings support the ASMBS 2019 guidelines for administering UDCA after LSG for preventing gallstone disease.

Indexed as

GallstonesGastrectomyUrsodeoxycholic AcidHumansLaparoscopyObesity, MorbidPostoperative ComplicationsRetrospective StudiesUrsodeoxycholic AcidGallstonesLaparoscopic sleeve gastrectomyUrsodeoxycholic acid

Identifiers

PMID36952047
OpenAlexW4360600697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.